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Figure 1. A, Conventional radiograph of the thorax showing bilateral pneumonia and pleural effusion. B, CT scan of the T12 vertebra showing
erosions caused by spondylitis (arrows) and severe decalcification caused by osteoporosis.
Spondylitis and Arthritis Due
to Mycoplasma hominis:
The Case for Awareness in
Undefined Pleuropneumonia
Sir—Mycoplasma hominis rarely causes
pneumonia [1]. Because special culture
media are required to detect M. hominis
and are not often requested, the lack of
clinical suspicion and/or detection may re-
sult in inappropriate treatment. As a con-
sequence, the risk of bacterial seeding is
increased, as is shown in the case we
report.
A 48-year-old woman with a history of
primary hypogammaglobulinemia was
hospitalized because of osteoporotic frac-
ture of the T12 vertebra. Her medical his-
tory included recurrent pneumonia, poly-
arthritis, and chondrocalcinosis of the
right knee. Five weeks after admission to
the hospital, she developed bilateral pneu-
monia (figure 1), which deteriorated to
ventilator-dependent respiratory failure,
despite treatment with amoxicillin-clavu-
lanate followed by treatment with ceftriax-
one plus clarithromycin. Results of cul-
tures of blood, urine, and pleural effusion
specimens were negative for pathogens; re-
sults of a urinary antigen test for Legionella
pneumophila and a PCR assay for Myco-
plasma pneumoniae were negative. Citro-
bacter species and Candida albicans grew
from samples of tracheal aspirate. Hence,
treatment was switched to imipenem-
cilastatin plus fluconazole, and immuno-
globulins (200 mg/kg) were substituted
once a week. Pansinusitis caused by Ci-
trobacter species was confirmed, and fluid
was drained. However, the patient’s con-
dition did not improve, and pulmonary
infiltrates persisted. Results of sero-
logical tests (for M. pneumoniae, Chla-
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mydia pneumoniae, Chlamydia tracho-
matis, Chlamydia psittaci, parvovirus B19,
rubella, Borrelia burgdorferi, and HIV)
were negative. Eight days after the patient
underwent intubation, skin inflammation
was observed at the level of the vertebral
fracture. A CT scan showed erosions and
severe decalcification (figure 1). Two
weeks later, swelling of the right knee oc-
curred. Arthrocentesis yielded 30 mL of
cloudy yellow synovial fluid with 24,300
cells/mL (92% neutrophils) and calcium
pyrophosphate crystals. Results of addi-
tional standard cultures and PCR for B.
burgdorferi and M. pneumoniae were neg-
ative. Needle aspiration of the T12 ver-
tebra was performed, and M. hominis was
identified using broad-spectrum eubacter-
ial PCR. In the meantime, M. hominis
grew in cultures of samples of synovial
fluid. Thus, systemic M. hominis infection
with arthritis and spondylitis was diag-
nosed. Clinical and laboratory findings
rapidly improved during treatment with
doxycycline (200 mg/day), and pulmo-
nary infiltrates regressed.
M. hominis is a commensal of humans
and mainly causes genitourinary tract in-
fection [2]. The patient described here had
neither a recent infection nor recent ma-
nipulation of the genitourinary tract. Ex-
tragenitourinary infections caused by M.
hominis, such as arthritis, spondylitis,
brain abscess, meningitis, and respiratory
tract infections have rarely been reported
[3]. Most of these cases, much like the case
we report, occurred in an immunocom-
promised host [1, 4]. In the case that we
report, it is likely that the primary infec-
tion was pleuropneumonia due to M.
hominis, because of the sequence of man-
ifestations of infection and because of the
favorable course of pneumonia only after
administration of doxycycline. It is inter-
esting that M. hominis was seeding to 2
foci that had previous pathologic find-
ings—namely, the fractured vertebra and
the knee that had active crystal synovitis—
illustrating that these sites of inflammation
represented a locus minoris resistentiae.
Antibiotic therapy for M. hominis is not
standardized and depends on the type of
infection. Tetracyclines are given mainly
for bone and joint infections. However,
resistant strains of M. hominis have been
reported [5]. Clindamycin, erythromycin,
and ciprofloxacin are documented alter-
natives but are not used as first-line ther-
apy [1, 4]. In the case of culture-negative
pleuropneumonia, clinical awareness of
M. hominis is important, so that specific
culture media can be requested and organ
failure and bacterial seeding can be
prevented.
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Chlamydia pneumoniae
and Asthma in Children:
Diagnostic Issues
Sir—We refer to the recent article by Bis-
cardi et al. [1] on the association between
atypical respiratory pathogens and asthma
in children, specifically the methods used
for determining Chlamydia pneumoniae
infection. Although the study was pri-
marily concerned with the role of Myco-
plasma pneumoniae, PCR and serologic
testing with an EIA were also performed
for diagnosis of C. pneumoniae infection.
But these tests have significant limitations.
PCR testing for C. pneumoniae is not stan-
dardized. Although there are more than
18 such in-house tests described in the
literature [2], none, including the assay
used by Biscardi et al. [1], has been ade-
quately validated by comparison with cul-
ture for respiratory-tract specimens. Re-
cent data also suggest major problems
with both inter- and intralaboratory re-
producibility, especially with nested assays
[3, 4]. The EIA used by Biscardi et al. [1]
has also not been validated in comparison
with culture or validated PCR for respi-
ratory infection [2]. The Centers for Dis-
ease Control has recommended the mi-
croimmunofluorescence (MIF) assay as
the serologic method of choice, although
this assay is also subject to interlaboratory
variability [5].
One issue not addressed at all is the
poor correlation between C. pneumoniae
serologic test results and results of culture
for children. Emre et al. [6] and several
other studies not cited [7–9] have docu-
mented that the majority of children with
culture-documented C. pneumoniae infec-
tion are seronegative by MIF assay. This
doesn’t mean that these children do not
have anti–C. pneumoniae antibody, but
that the antibodies they do make are not
detected by the MIF [9]. Because the EIA
used by Biscardi et al. [1] (ELISA-Chla-
mydia, Savyon) uses whole C. pneumoniae
elementary bodies as the antigen, one
would expect results similar to the MIF
assay, which also uses whole elementary
bodies. As expected, results of EIA sero-
